Annovis Bio Inc. (NYSE: ANVS) NYSE Compliance Plan FAQ

What is the main topic of the press release?

The press release announces that Annovis Bio Inc. has received formal acceptance from the NYSE for its compliance plan, granting the company an 18-month window to regain compliance with minimum market capitalization and stockholders’ equity requirements.

Why is this compliance window significant for Annovis Bio?

This compliance window allows Annovis Bio to continue trading on the NYSE while it works to meet the necessary financial requirements, ensuring no immediate impact on its operations, business activities, or SEC reporting obligations.

How long is the compliance window granted to Annovis Bio?

The NYSE has granted Annovis Bio an 18-month compliance window, beginning on March 26, 2025.

What must Annovis Bio do during the compliance window?

Annovis Bio must meet the milestones outlined in its compliance plan and adhere to all other NYSE listing requirements to continue trading on the exchange during the 18-month period.

Does this NYSE notification affect Annovis Bio’s operations?

No, the notification has no impact on Annovis Bio’s operations, business activities, or SEC reporting obligations.

Where can I find more information about Annovis Bio?

More information about Annovis Bio can be found on their website at www.AnnovisBio.com and their social media channels on LinkedIn, X, and YouTube.

What is Annovis Bio’s focus?

Annovis Bio is focused on developing innovative therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, aiming to restore brain function and improve patients’ quality of life.

Where is Annovis Bio headquartered?

Annovis Bio is headquartered in Malvern, Pennsylvania.

How can investors stay updated on Annovis Bio’s news?

Investors can stay updated on Annovis Bio’s latest news and updates by visiting the company’s newsroom at https://ibn.fm/ANVS.

What is InvestorWire’s role in this press release?

InvestorWire is a specialized communications platform that provided press release syndication services for this announcement, part of the Dynamic Brand Portfolio @ IBN, aimed at reaching a wide audience of investors and the general public.